CN101816643A - Medicament composition containing diclofenac sodium and acetaminophen - Google Patents
Medicament composition containing diclofenac sodium and acetaminophen Download PDFInfo
- Publication number
- CN101816643A CN101816643A CN200910266012A CN200910266012A CN101816643A CN 101816643 A CN101816643 A CN 101816643A CN 200910266012 A CN200910266012 A CN 200910266012A CN 200910266012 A CN200910266012 A CN 200910266012A CN 101816643 A CN101816643 A CN 101816643A
- Authority
- CN
- China
- Prior art keywords
- acetaminophen
- diclofenac sodium
- weight portion
- weight
- propylene glycol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 title claims abstract description 163
- 229960005489 paracetamol Drugs 0.000 title claims abstract description 91
- 229960001193 diclofenac sodium Drugs 0.000 title claims abstract description 79
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 title claims abstract description 67
- 239000000203 mixture Substances 0.000 title claims abstract description 21
- 239000003814 drug Substances 0.000 title abstract description 12
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 30
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 30
- 239000002904 solvent Substances 0.000 claims abstract description 14
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 105
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 27
- 239000008194 pharmaceutical composition Substances 0.000 claims description 26
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 12
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 6
- 239000008215 water for injection Substances 0.000 claims description 6
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 claims description 4
- 235000019345 sodium thiosulphate Nutrition 0.000 claims description 4
- 239000004201 L-cysteine Substances 0.000 claims description 3
- 235000013878 L-cysteine Nutrition 0.000 claims description 3
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims description 3
- 235000010262 sodium metabisulphite Nutrition 0.000 claims description 3
- 238000006116 polymerization reaction Methods 0.000 claims description 2
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 abstract description 8
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 abstract 2
- 239000000243 solution Substances 0.000 description 29
- 238000002360 preparation method Methods 0.000 description 18
- 229940090044 injection Drugs 0.000 description 17
- 238000002347 injection Methods 0.000 description 17
- 239000007924 injection Substances 0.000 description 17
- PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical compound NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 238000002425 crystallisation Methods 0.000 description 11
- 230000008025 crystallization Effects 0.000 description 11
- 238000012360 testing method Methods 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 230000001954 sterilising effect Effects 0.000 description 7
- 238000004659 sterilization and disinfection Methods 0.000 description 7
- 206010018910 Haemolysis Diseases 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 230000008588 hemolysis Effects 0.000 description 6
- 229960001259 diclofenac Drugs 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- -1 acetophenone amine Chemical class 0.000 description 4
- 229960001138 acetylsalicylic acid Drugs 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 150000003180 prostaglandins Chemical class 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000002421 anti-septic effect Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 208000029618 autoimmune pulmonary alveolar proteinosis Diseases 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 229960004126 codeine Drugs 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 3
- 238000005286 illumination Methods 0.000 description 3
- 239000012982 microporous membrane Substances 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 239000004576 sand Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N Propene Chemical group CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- 229960000711 alprostadil Drugs 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000000589 cicatrix Anatomy 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000005057 refrigeration Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- UXFQFBNBSPQBJW-UHFFFAOYSA-N 2-amino-2-methylpropane-1,3-diol Chemical compound OCC(N)(C)CO UXFQFBNBSPQBJW-UHFFFAOYSA-N 0.000 description 1
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Natural products CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 206010038419 Renal colic Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 229940086216 acetaminophen 150 mg Drugs 0.000 description 1
- 229940086244 acetaminophen 600 mg Drugs 0.000 description 1
- 229940050447 acetaminophen injection Drugs 0.000 description 1
- 229940016213 acetaminophen oral solution Drugs 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000003026 anti-oxygenic effect Effects 0.000 description 1
- 239000003907 antipyretic analgesic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 229940100955 diclofenac sodium 100 mg Drugs 0.000 description 1
- 229940100873 diclofenac sodium 50 mg Drugs 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical class OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 159000000000 sodium salts Chemical group 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention provides a medicament composition containing diclofenac sodium and acetaminophen, comprising acetaminophen and diclofenac sodium as active components, and propanediol and polyethylene glycol as solvents, wherein the weight ratio of the acetaminophen to the diclofenac sodium is 1:0.1 to 1; 1 to 6 weight portions of propanediol are used for each weight portion of acetaminophen; and 1 to 5 weight portions of polyethylene glycol are used for each weight portion of acetaminophen. The composition can be used as an analgesic, and has good solubility and medicament stability.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition, relate more specifically to a kind of injection.
Background technology
Acetaminophen (APAP) is an acetophenone amine antipyretic analgesic.By suppressing hypothalamus thermotaxic centre prostaglandin synthetase, reduce the synthetic and release of Prostaglandin PGE1, cause the peripheral blood vessel expansion, perspire and reach the antipyretic effect, its refrigeration function intensity is similar to aspirin; By suppressing the synthetic of Prostaglandin PGE1, Kallidin I and histamine etc. and discharge, improve the threshold of pain and play analgesic activity, belong to the periphery analgesic, effect is than a little less than the aspirin, only to light, moderate pain is effective.This product does not have the obvious anti-inflammatory and anti effect.
In fact, similar with aspirin, acetaminophen shows its activity by the synthesizing of prostaglandin of suppressing to be produced by COX-2.Yet, be different from most of nonsteroidal antiinflammatory drugs (NSAID), its inhibitory action almost only works to brain and the effect of peripheral tissues's (stomach, kidney and platelet) is in extremely low level, owing to this reason, it uses side effect such as the heartburn and the gastric damage that can not produce typical N SAID, follows possible losing blood.
The unique possible complication relevant with its application is hepatolysis, and (Flower R., " nature " (Nature) 240,410-411,1972 although this situation only takes place under the situation of overdose; Lanz R., poster p. " pharmacology's magazine " (J.Pharmacol.) 130,105-109,1986; Black M., " medicine yearbook " (Annual Reviews ofMedicine) 35,577-593,1984).
Diclofenac (DS) is a kind of non-steroidal anti-inflammatory analgesics that is derived from the phenylacetic acid class, is that effect is stronger a kind of in the non-steroidal antibiotic medicine, and it is better than aspirin and indomethacin etc. to the synthetic inhibitory action of prostaglandin.Be mainly used in the verification treatment of the acute pain that causes after the heating of various febrile diseases and renal colic, serious symptom rheumatoid arthritis and osteoarthritis, acute gout, acute wound, fracture and the operation.The per injection administration needs 50mg.
Diclofenac is often used with the pharmaceutically acceptable sodium salt form; its oral medical value is approved by clinical; but compare injection; its bioavailability and onset speed also are not very desirable; and oral administration regular meeting causes some gastrointestinal reactions; so the injection of diclofenac is worth further research and development, especially compound preparation.When itself and acetaminophen drug combination, then can remedy the other side's defective mutually, have mutual synergism, both had anti-inflammatory analgesic action, have antipyretic effect again.
In order to reduce toxic and side effects, reduce single-dose dosage, compound preparation becomes primary goal in research.
Experimental study is the result show: the compound preparation that contains diclofenac sodium+acetaminophen has stronger refrigeration function. and its obvious effective rate is 92.94%, and total effective rate is 100%; And the obvious effective rate of matched group 1 (containing diclofenac sodium 50mg) is 83.91%, total effective rate is 98.85%, and the obvious effective rate of matched group 2 (containing acetaminophen 150mg) is 81.71%, and total effective rate is that 94.68%, three group curative effect does not relatively have remarkable significant difference; But the fever time of compound preparation injection is very fast.54 examples (63.5%) began to bring down a fever in 15 minutes, and matched group 1 then is 39 to fall (44.9%), and 2 of matched groups are 32 to fall (36.9%), and three groups relatively, has significant difference (P＜0.05) to illustrate that diclofenac and acetaminophen have certain synergism.
But known acetaminophen is slightly soluble in water (" the 12nd edition the 9th page of No 45,1996 of Merck index (The Merck Index)).70ml water can only dissolve 1g acetaminophen (1996 15 4 phases of volume of " solubilization studies of acetaminophen oral solution " " Shandong medical industry "); Diclofenac sodium (DS) dissolubility in water less (9mg/ml, 25 ℃); The both does not reach the formulation concentrations requirement.In addition, under the situation that water exists, acetaminophen produces the degraded of pink to brown derivant.The degraded of common type is to be hydrolyzed into para-aminophenol (PAP) and/or by for example oxygen oxidation soluble in water.And still contain easy oxide group in the molecular structure of DS, as after being made into injection, can make the stability decreases of medicine, these features are represented their major obstacles by the drug administration by injection existence.Therefore seek suitable solvent system and improve the key issue that preparation stability becomes research.
For the research report and the patent of invention of the administration concentration that improves diclofenac sodium or acetaminophen more.As patent application WO98/05314, CN1711996A, 2007 23 the 23rd phases of volume of " technology of acetaminophen injection and quality research " modern medicine health etc. report is arranged all.
But improve injection diclofenac sodium and acetaminophen compound preparation administration concentration the research report and patent of invention is still little sees.Only " acetaminophen, diclofenac compound preparation prescription overview and prospect " 2005 the 26th the 2nd phases of volume of Shanghai medicine go up on the books.
Especially, described in above-mentioned document, the mixed solution of being made up of 30% propylene glycol, 40%PEG-400 and 30% water can be under 20 ℃ be dissolved to acetaminophen many 200mg/ml (WO98/05314, the 9th page of 7-12 is capable).Also by reporting the mixed solution that adopts 50% propylene glycol and 50% water to form; Or 10% the mixed solution formed of ethanol and 40% Polyethylene Glycol and 50% water acetaminophen can be dissolved to many 250mg/ml (CN1146413C).
Yet the above two mix extremely sticking (referring to comparative example 1) this solvent, produce cicatrix (weals) side effect when haemolysis and injection are arranged; The latter is big because of containing the ethanol zest, and especially is unsuitable for passing through drug administration by injection.And be dissolved to the diclofenac sodium of many 12.5mg/ml and the compound preparation of 75mg/ml acetaminophen still has poor stability by the mixed solution that secular low-temperature study 50% propylene glycol and 50% water are formed, idol has crystallization to separate out phenomenon.
Therefore, based on still existing to except that diclofenac sodium that contains treatment level and acetaminophen, can also easily injecting and can not produce the very big demand of the pharmaceutical composition of cicatrix (weals).Experimentation, diclofenac sodium and acetaminophen drug combination had both overcome acetaminophen does not have the obvious anti-inflammatory and anti effect, has strengthened the diclofenac sodium anti-inflammatory analgesic action again, and significantly reduces individually dosed single dose, clinically see that side effect reduces, and safer.
Summary of the invention
The object of the present invention is to provide a kind of pharmaceutical composition, to overcome the stability and the drug safety problem of diclofenac sodium and acetaminophen compound recipe in the prior art with specific solvent component.
A first aspect of the present invention provides a kind of pharmaceutical composition, it comprises as the acetaminophen of active component and diclofenac sodium, and as the propylene glycol and the Polyethylene Glycol of solvent, wherein, the weight ratio of acetaminophen and diclofenac sodium is 1: 0.1-1, the propylene glycol of the 1-6 weight portion that every weight portion acetaminophen uses, the Polyethylene Glycol of the 1-5 weight portion that every weight portion acetaminophen uses.
A second aspect of the present invention provides a kind of pharmaceutical composition, it comprises as the acetaminophen of active component and diclofenac sodium, and as propylene glycol, Polyethylene Glycol and the water of solvent, wherein, the weight ratio of acetaminophen and diclofenac sodium is 2-10: 1, and the diclofenac sodium of every weight portion uses propylene glycol, the Polyethylene Glycol of 5-15 weight portion and the water that is not less than the 50-80 weight portion of 15-25 weight portion.
In pharmaceutical composition according to the present invention, active component can be dissolved in the solvent well, and presents good stability.In addition, adopt pharmaceutical composition of the present invention, the curative effect that not only shows, and haemolysis does not appear.
The specific embodiment
The inventor is surprised to find that: Polyethylene Glycol can promote the dissolving in propylene glycol of diclofenac sodium and acetaminophen.And stability is better.
As viewed in an embodiment, by the mixture of propylene glycol and Polyethylene Glycol the amount (embodiment 1) of dissolved diclofenac sodium and acetaminophen be higher than the independent low propylene glycol alcohol of weight such as using or Polyethylene Glycol dissolving amount to diclofenac sodium and acetaminophen.
Of the present invention aspect first, a kind of pharmaceutical composition is provided, it comprises as the acetaminophen of active component and diclofenac sodium, and as the propylene glycol and the Polyethylene Glycol of solvent, wherein, the weight ratio of acetaminophen and diclofenac sodium is 1: 0.1-1, preferred 1: 0.1-0.35, more preferably 1: 0.15-0.25, most preferably 6: 1; Every weight portion acetaminophen uses the propylene glycol of 1-6 weight portion.Be no more than under half the situation of acetaminophen at the diclofenac sodium consumption, every weight portion acetaminophen preferably uses 2-4 weight portion, the more preferably propylene glycol of 2.5-3.0 weight portion; The Polyethylene Glycol of the 1-5 weight portion that every weight portion acetaminophen uses, be no more than under half the situation of acetaminophen at the diclofenac sodium consumption, every weight portion acetaminophen preferably uses 2-4 weight portion, the more preferably Polyethylene Glycol of 2.5-3.0 weight portion.
Can suitably regulate the consumption of used propylene glycol and Polyethylene Glycol according to the acetaminophen and the relative weight ratio of diclofenac sodium.Generally speaking, along with the increase of diclofenac sodium consumption, the consumption of corresponding increase propylene glycol and Polyethylene Glycol.
Use the organic solvent of aforementioned proportion can guarantee that acetaminophen and diclofenac sodium in above-mentioned scope can dissolve well.Because this pharmaceutical composition is not moisture substantially, active component wherein can not separated out from solvent, has excellent stability.In addition, because this double solvents is very low to the dissolubility of oxygen, said composition has good antioxygenic property, though do not have antioxidant in the presence of, active substance also can be in the system of opening wide stable existence.
Because this aforementioned pharmaceutical compositions can also further contain other auxiliary elements, for example antioxidant, antiseptic etc.
It should be noted that when using this pharmaceutical composition, should use the water of 6-10 weight for every weight portion acetaminophen, said composition is deployed into the clear and bright solution of injection.This clear and bright liquid should configure in back 2 hours, is preferably in 1 hour to use.Use the water of this ratio can avoid haemolysis after medicine enters human body well.
Adult's consumption generally is controlled to be acetaminophen 150-600mg. every day.Diclofenac sodium then is corresponding proportion compatibility.
The diclofenac sodium of first aspect of the present invention and the organic solution of acetaminophen are very stable, this be because even 121 ℃ of down sterilizations 30 minutes, subsequently 30 ℃ and 11,000 rein in down constant illumination store at least 1 month after acetaminophen can not be precipitated out or degrade.Even do not having antiseptic, stabilizing agent, surfactant, buffer agent, be used to catch under the reagent of free radical and/or the situation that antioxidant exists and found this stability yet.
Aspect second of the present invention, relate to a kind of pharmaceutical composition by the clear and bright solution composition of injection, it comprises as the acetaminophen of active component and diclofenac sodium, and as propylene glycol, Polyethylene Glycol and the water of solvent, wherein, the weight ratio of acetaminophen and diclofenac sodium is 2-10: 1, and preferred 3-7: 1, more preferably 5-7: 1, most preferably 6: 1; For the diclofenac sodium of every weight portion, the weight portion of the propylene glycol that uses is 15-25, and preferred 18-22, most preferably 20; For the diclofenac sodium of every weight portion, the weight portion of the Polyethylene Glycol of use is preferably 5-15, and even more preferably 12; For the diclofenac sodium of every weight portion, the weight portion of the water of use is not less than 50, but is not higher than 80 usually.For example can use the water of 55,60,65 weight portions.
Can suitably regulate the consumption of used propylene glycol and Polyethylene Glycol according to the acetaminophen and the relative weight ratio of diclofenac sodium.Generally speaking, along with the increase of acetaminophen consumption, the consumption of corresponding increase propylene glycol and Polyethylene Glycol.
Use the organic solvent of aforementioned proportion can guarantee that acetaminophen and diclofenac sodium in above-mentioned scope can dissolve well.Owing to adopted above-mentioned specific solvent ratios, active component wherein also can steady in a long-termly exist, and is difficult for separating out from water.In addition, when said composition is used as final injection, can not cause haemolysis yet.
In general, the clear and bright aqueous solution of thus obtained injection has the viscosity of 2-10mPa.s.The preferred consumption of adjusting low propylene glycol, Polyethylene Glycol and water makes that described viscosity is 4-7mPa.s.
Adult's consumption generally is controlled to be acetaminophen 150-600mg every day.Diclofenac sodium then is corresponding proportion compatibility.
This solution also have the reagent that do not contain any antiseptic, stabilizing agent, surfactant, buffer agent, be used to catch free radical and/or further advantage.
The degree of polymerization that can be used for Polyethylene Glycol of the present invention can preferably between 300-1000, more preferably between 300-600, most preferably be 400 between 200 to 4000.
Use propylene glycol can be 1,2-propylene glycol and 1, ammediol among the present invention.
Can prepare pharmaceutical composition of the present invention according to well-known technology in the pharmaceutical chemistry that comprises steps such as mixing, dissolving, sterilization.
Further describe the present invention by the following example, these embodiment that provide are used to the purpose of explaining merely and should not be taken the implication of qualification.
Embodiment 1
Solution A is formed
The composition consumption
Diclofenac sodium 15g
L-cysteine 1g
Acetaminophen 75g
1.2-propylene glycol 200g
PEG-400???????????200g
Preparation
At room temperature, add diclofenac sodium and acetaminophen then with 1.2-propylene glycol, PEG-400, L-cysteine dissolving mixing.Till this mixture is stirred to diclofenac sodium and acetaminophen and dissolves fully (about 30 minutes).Solution filters by active carbon layer sand rod earlier, passes through filtering with microporous membrane again.Thus obtained solution is divided in about 400 ampoules, every bottled 1ml, sterilization is promptly.
Some samples to preparation (0 o'clock) recently carry out following check:
-diclofenac sodium titre, HPLC (mg/ml);
-para-aminophenol titre: HPLC (mg/ml);
Any painted catabolite of-detection: the spectrophotography at 475nm place;
-clarity: detect by official method in 2005.
The result who obtains is as follows:
-diclofenac sodium average titer: 14.6;
-acetaminophen average titer: 74.8;
-para-aminophenol: do not have
-average absorption degree: 0.0075
-clarity: achromatism and clarity solution
Then above-mentioned sample was stored 1 month under following condition, tested its stability then, test result is listed in the table 1.Wherein, sample a stores down at 4 ℃, and sample b at room temperature stores, and sample c is in the indoor storage of 30 ℃ and 11,000 illuminations of reining in.
Table 1
| Sample | ??DS??(mg/ml) | ??APAP??(mg/ml) | ??PAP??(mg/ml) | Trap (475nm) | Clarity |
| ??a | ??14.9 | ??74.8 | ??0.00 | ??0.0039 | Clear and bright |
| ??b | ??14.6 | ??75.2 | ??0.00 | ??0.0042 | Clear and bright |
| ??c | ??14.7 | ??74.6 | ??0.00 | ??0.0125 | Clear and bright |
PAP represents p-aminophenol
As can be seen from Table 1: adopt the sample of embodiment 1 preparation stable under above-mentioned condition stores.
(sample d) shows following properties by other sample for preparing () with quadrat method recently at 0 o'clock;
-diclofenac sodium titre: 14.6
-acetaminophen titre: 74.6
-para-aminophenol: do not have
-trap: 0.0032
-clarity: clear and bright, no crystallization is separated out
At 25 ℃ with listing they is kept at indoor 12 months under the terms of packing and they show following properties:
-diclofenac sodium titre: 14.5
-acetaminophen titre: 74.2
-para-aminophenol: 0.008
-trap: 0.0082
-clarity: clear and bright, no crystallization is separated out
By preparing () recently at 0 o'clock with quadrat method and the sample (sample e) of sterilization after (121 ℃, 30 minutes) shows following feature:
-diclofenac sodium: 14.6
-acetaminophen titre: 74.5
-para-aminophenol: do not have
-trap: 0.0048
-clarity: clear and bright, no crystallization is separated out
Descending at 30 ℃ and 11,000 lighting conditions of reining in, they are kept at indoor 1 month and they show following properties:
-diclofenac sodium: 14.4
-acetaminophen titre: 74.0
-para-aminophenol: do not have
-trap: 0.0049
Clarity: clear and bright, no crystallization is separated out
Above result shows: adopt the sample of embodiment 1 preparation to place stable for a long time down at above-mentioned condition of storage.
In brief, qualified according to the described pharmaceutical composition content of invention first aspect from the result of embodiment 1 as can be seen, good stability, no crystallization or precipitate produce.
During use, the solution A 1 (1ml/ props up) of getting as above-mentioned embodiment 1 method preparation adds 1ml water for injection, uses the hands jolting until forming the clear and bright solution of a kind of injection (about 30 seconds) then.
Thus obtained solution shows following properties:
Outward appearance is clear and bright, and is colourless
Viscosity * (mPa.s) 5.128
The Morie osmolarity of calculating (mosmol/ liter) 526.1
Density * * (g/ml) 1.0230
Embodiment 2
Solution B is formed
The composition consumption
Diclofenac sodium 25g
Sodium pyrosulfite 2g
Acetaminophen 75g
1,2-propylene glycol 250g
PEG-400?????????????200g
Water for injection adds to 1000ml
Preparation
At room temperature with 1,2-propylene glycol, PEG-400, sodium pyrosulfite dissolving mixing add in diclofenac sodium and the acetaminophen.Till then this mixture being stirred to diclofenac sodium and acetaminophen and dissolving fully (about 30 minutes).Adjust pH value to 7-9 with sodium hydroxide solution, solution filters by active carbon layer sand rod earlier, passes through filtering with microporous membrane again.Thus obtained solution is divided in about 500 ampoules, every bottled 2ml, sterilization is promptly.
Some samples to preparation (0 o'clock) recently carry out following check:
-diclofenac sodium titre, HPLC (mg/ml);
-para-aminophenol titre: HPLC (mg/ml);
Any painted catabolite of-detection: the spectrophotography at 475nm place;
-clarity: detect by official method in 2005
The result who obtains is as follows:
-diclofenac sodium average titer: 24.6;
-acetaminophen average titer: 74.8;
-para-aminophenol: do not have
-average absorption degree: 0.0075
-clarity: clear and bright, no crystallization is separated out
Then above-mentioned sample was stored 1 month under following condition, tested its stability then, with the results are shown in the following table 2 of obtaining.Wherein, sample a ' stores down at 4 ℃, and sample b ' at room temperature stores, and sample c ' is in the indoor storage of 30 ℃ and 11,000 illuminations of reining in.
Table 2
| Sample | ??DS??(mg/ml) | ??APAP??(mg/ml) | ??PAP??(mg/ml) | The trap of 475nm | Clarity |
| ??a′ | ??24.9 | ??74.8 | ??0.00 | ?0.0039 | Clear and bright |
| ??b′ | ??24.6 | ??75.2 | ??0.00 | ?0.0042 | Clear and bright |
| ??c′ | ??24.7 | ??74.6 | ??0.00 | ?0.0125 | Clear and bright |
As can be seen from Table 2: adopt the sample of embodiment 1 preparation stable under above-mentioned condition stores
Recently other sample for preparing () by embodiment 2 at 0 o'clock shows following properties;
-diclofenac sodium titre: 24.6
-acetaminophen titre: 74.0
-para-aminophenol: do not have
-trap: 0.0032
At 25 ℃ with listing they is kept at indoor 12 months under the terms of packing and they show following properties:
-diclofenac sodium titre: 24.3
-acetaminophen titre: 74.5
-para-aminophenol: do not have
-trap: 0.0086
Clarity: clear and bright, no crystallization is separated out
The sample (sample V) that embodiment 2 prepares after (0 o'clock) and the sterilization (121 ℃, 30 minutes) recently shows following feature:
-diclofenac sodium: 24.2
-acetaminophen titre: 74.4
-to the stupid phenol of amino: do not have
-trap: 0.0048
-clarity: clear and bright, no crystallization is separated out
Descending at 30 ℃ and 11,000 lighting conditions of reining in, they are kept at indoor 1 month and they show following properties:
-diclofenac sodium: 23.8
-acetaminophen titre: 74.0
-to the stupid phenol of amino: do not have
-trap: 0.0051
-clarity: clear and bright, no crystallization is separated out
In brief, qualified according to the described pharmaceutical composition content of invention first aspect from the result of embodiment 1-3 as can be seen, good stability, no crystallization or precipitate produce.
Embodiment 3
Solution C
The composition consumption
Diclofenac sodium 7.5g
Sodium thiosulfate 2g
Acetaminophen 75g
A 1.2 propylene glycol 200g
PEG-400???????????200g
Water for injection adds to 1000ml
Solution D
The composition consumption
Diclofenac sodium 12.5g
Sodium thiosulfate 2g
Acetaminophen 75g
A 1.2 propylene glycol 150g
PEG-400???????????200g
Water for injection adds to 1000ml
The same solution B of compound method
At room temperature, add in diclofenac sodium and the acetaminophen 1.2 1 propylene glycol, PEG-400, sodium thiosulfate dissolving mixing.Till then this mixture being stirred to diclofenac sodium and acetaminophen and dissolving fully (about 30 minutes).Adjust pH value to 7-9, solution filters by active carbon layer sand rod earlier, passes through filtering with microporous membrane again.Thus obtained solution is divided in about 500 ampoules, every bottled 2ml, sterilization is promptly.Thus obtained solution shows following physicochemical characteristic:
| Detect index | Solution B | Solution C | Solution D |
| Outward appearance | Clear and bright, colourless | Clear and bright, colourless | Clear and bright, colourless |
| Viscosity * (mPa.s) | ??5.068 | ??5.125 | ??5.116 |
| The Morie osmolarity of calculating (m0smol/ liter) | ??529.2 | ??530.6 | ??532.7 |
| Density * * (g/ml) | ??1.02600 | ??1.02765 | ??1.02791 |
Pharmacological evaluation:
Analgesic test: adopt hot plate method, measured diclofenac sodium and acetaminophen ED50 value separately, respectively cooperate then and obtain 3 kinds of composition of medicine in 4/5: 1/5,1/2: 1/2,1/5: 4/5 ratio, find that they are respectively 1.26,1.12 and 1.50 times of theoretical value to the analgesic effect of mice, clear and definite this synergism on the dose-effect relationship.
Hemolytic test: the sample with solution B is tested
A certain amount of test sample is added in the 2% Sanguis Leporis seu oryctolagi normal saline suspension, and observation has or not haemolysis and agglutination phenomenon, as one of injection safety inspection project.
The preparation of (one) 2% Sanguis Leporis seu oryctolagi normal saline suspension is from healthy rabbits ear vein or heart extracting blood 2ml, adds normal saline and is diluted to 100ml and shakes up promptly.
(2) the test sample weighing apparatus preparation first liquid of releasing liquid is got need testing solution 0.5ml, adds normal saline and is diluted to 100ml, shakes up promptly.Second liquid is got the need testing solution 1.0ml of injection for intravenous, adds normal saline and is diluted to 10ml, shakes up promptly.
(3) test method is got 3 of clean tube, adds various solution in the following order, and each pipe shakes up, and puts to leave standstill in 37 ℃ of waters bath with thermostatic control and observes 1 hour.
Test tube 1 pipe 2 pipes 3 pipes
Sample B diluent (first) 2ml--
Sample B diluent (second)-2ml-
The normal saline contrast--2ml
2% Sanguis Leporis seu oryctolagi suspension 2ml 2ml 2ml
The 1st pipe, the 2nd pipe, the 3rd pipe matched group do not have haemolysis and agglutination phenomenon generation
Adopt the product of solution D to carry out clinical trial, carried out a double blinding, at random, parallel study, 60 tumor operation patients usefulness acetaminophen 600mg, diclofenac sodium 100mg before the operation beginning.Intra-operative and the pain relieving of used after operation codeine, the consumption of codeine is determined by the self-administered cover controlled analgesia system of patient, found that with independent use acetaminophen and compare, still have enough analgesic activities even two medicines and time spent codeine consumption reduce nearly 40%.
The explanation of the specific embodiment of front can disclose general features of the present invention fully, so that other people are easily concrete application by existing knowledge these specific embodiment are adjusted and/or adaptations, these all do not depart from scope of the present invention, so these adjustment and revise the replacement that is equal to be considered as embodiment disclosed in the present invention.Should also be understood that simultaneously expression herein or technical term are for illustrative purposes, rather than be used to limit its implication.
Claims (10)
1. pharmaceutical composition, it comprises as the acetaminophen of active component and diclofenac sodium, and as the propylene glycol and the Polyethylene Glycol of solvent, wherein, the weight ratio of acetaminophen and diclofenac sodium is 1: 0.1-1, the propylene glycol of the 1-6 weight portion that every weight portion acetaminophen uses, the Polyethylene Glycol of the 1-5 weight portion that every weight portion acetaminophen uses.
2. pharmaceutical composition according to claim 1, wherein, the weight ratio of acetaminophen and diclofenac sodium is 1: 0.1-0.35, and every weight portion acetaminophen uses the propylene glycol of 2-4 weight portion, and every weight portion acetaminophen uses the Polyethylene Glycol of 2-4 weight portion.
3. pharmaceutical composition according to claim 2, wherein, the weight ratio of acetaminophen and diclofenac sodium is 1: 0.15-0.25, every weight portion acetaminophen uses the propylene glycol of 2.5-3.0 weight portion and the Polyethylene Glycol of 2.5-3.0 weight portion.
4. pharmaceutical composition according to claim 1, the degree of polymerization of wherein said Polyethylene Glycol is between 300-600.
5. pharmaceutical composition according to claim 1, wherein said Polyethylene Glycol are PEG400.
6. pharmaceutical composition according to claim 1 comprises following composition:
Diclofenac sodium 15 weight portions
L-cysteine 1 weight portion
Acetaminophen 75 weight portions
1.2-propylene glycol 200 weight portions
PEG-400 200 weight portions.
7. pharmaceutical composition, it comprises as the acetaminophen of active component and diclofenac sodium, and as propylene glycol, Polyethylene Glycol and the water of solvent, wherein, the weight ratio of acetaminophen and diclofenac sodium is 2-10: 1, and the diclofenac sodium of every weight portion uses propylene glycol, the Polyethylene Glycol of 5-15 weight portion and the water that is not less than the 50-80 weight portion of 15-25 weight portion.
8. pharmaceutical composition according to claim 7, wherein, the weight ratio of acetaminophen and diclofenac sodium is 5-7: 1, and the diclofenac sodium of every weight portion uses propylene glycol, the Polyethylene Glycol of 12 weight portions and the water of 50-80 weight portion of 18-22 weight portion.
9. pharmaceutical composition according to claim 7 comprises following composition:
Diclofenac sodium 25 weight portions
Sodium pyrosulfite 2 weight portions
Acetaminophen 75 weight portions
1,2-propylene glycol 250 weight portions
PEG-400 200 weight portions
Water for injection adds to 1000 weight portions.
10. pharmaceutical composition according to claim 7 comprises following composition:
Diclofenac sodium 12.5 weight portions
Sodium thiosulfate 2 weight portions
Acetaminophen 75 weight portions
A 1.2 propylene glycol 150 weight portions
PEG-400 200 weight portions
Water for injection adds to 1000 weight portions.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200910266012 CN101816643B (en) | 2009-12-31 | 2009-12-31 | Medicament composition containing diclofenac sodium and acetaminophen |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200910266012 CN101816643B (en) | 2009-12-31 | 2009-12-31 | Medicament composition containing diclofenac sodium and acetaminophen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101816643A true CN101816643A (en) | 2010-09-01 |
| CN101816643B CN101816643B (en) | 2013-02-13 |
Family
ID=42652023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200910266012 Active CN101816643B (en) | 2009-12-31 | 2009-12-31 | Medicament composition containing diclofenac sodium and acetaminophen |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101816643B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102349887A (en) * | 2011-08-02 | 2012-02-15 | 天津市嵩锐医药科技有限公司 | Diclofenac sodium acetaminophen gastrointestinal type capsule medicinal composition |
| CN105982853A (en) * | 2015-03-17 | 2016-10-05 | 成都医学院 | Paracetamol infusion solution and preparation method and application thereof |
| WO2022232211A1 (en) * | 2021-04-28 | 2022-11-03 | Glaxosmithkline Consumer Healthcare Holdings (Us) Llc | Alkali metal salt combinations of incompatible active pharmaceutical ingredients |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106214632A (en) * | 2016-08-30 | 2016-12-14 | 天津市中升挑战生物科技有限公司 | A kind of acetaminophen, Diclofenac Sodium Injection and preparation method thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1301976B1 (en) * | 1998-07-31 | 2000-07-20 | Angelini Ricerche Spa | INJECTABLE PHARMACEUTICAL COMPOSITION BASED ON PARACETAMOL |
| CN101015542A (en) * | 2007-02-13 | 2007-08-15 | 天津生机集团有限公司 | Compound paracetamol injection for livestock and process for preparing same |
-
2009
- 2009-12-31 CN CN 200910266012 patent/CN101816643B/en active Active
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102349887A (en) * | 2011-08-02 | 2012-02-15 | 天津市嵩锐医药科技有限公司 | Diclofenac sodium acetaminophen gastrointestinal type capsule medicinal composition |
| CN105982853A (en) * | 2015-03-17 | 2016-10-05 | 成都医学院 | Paracetamol infusion solution and preparation method and application thereof |
| CN105982853B (en) * | 2015-03-17 | 2019-03-29 | 成都医学院 | Big infusion of a kind of paracetamol and its preparation method and application |
| WO2022232211A1 (en) * | 2021-04-28 | 2022-11-03 | Glaxosmithkline Consumer Healthcare Holdings (Us) Llc | Alkali metal salt combinations of incompatible active pharmaceutical ingredients |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101816643B (en) | 2013-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021165312A (en) | Pharmaceutical composition containing loxoprofen | |
| JP7160433B2 (en) | Loxoprofen-containing topical preparation for skin | |
| CA2567075A1 (en) | Pharmaceutical suspension composition | |
| KR20160148723A (en) | Enhanced stability of novel liquid compositions | |
| EP1893190A2 (en) | Methods and compositions for treating pain | |
| JP2022105134A (en) | Pharmaceutical compositions containing loxoprofen (5) | |
| KR20150050595A (en) | Formulations of low dose diclofenac and beta-cyclodextrin | |
| CN101214235A (en) | Ibuprofen amino acid salt injection and preparation thereof | |
| CN101816643B (en) | Medicament composition containing diclofenac sodium and acetaminophen | |
| JP2018516266A (en) | Celecoxib oral composition for the treatment of pain | |
| CN102245167A (en) | Formulation for oral transmucosal administration of analgesic and/or antispasmodic molecules | |
| CN104622855A (en) | Oral solution containing ambroxol hydrochloride and salbutamol sulfate | |
| CN102603723A (en) | Azilsartan organic amine salts, and preparation method and application thereof | |
| US20050171203A1 (en) | Pregabalin composition | |
| US10548838B1 (en) | Oral liquid compositions including valsartan | |
| JP5872551B2 (en) | Pharmaceutical composition containing paracetamol and method for producing the same | |
| CN106511264A (en) | Methylphenidate hydrochloride oral solution and preparation method thereof | |
| TW201818921A (en) | Acetaminophen and tramadol cosolvent compound analgesic oral liquid capable of solving the problem associated with using oral analgesic lozenges due to difficulties in swallowing | |
| CN104418818B (en) | Parecoxib sodium anhydrous compound | |
| CN105769756B (en) | A kind of fumaric acid Sitafloxacin hydrate injection and preparation method thereof | |
| CN103830171B (en) | A kind of Ketorolac tromethamine injection and preparation method thereof | |
| CN102166206B (en) | Liquid oseltamivir phosphate composition | |
| CN110200905A (en) | A kind of ambroxol hydrochloride composition and its injection and application | |
| US11446243B1 (en) | Oral liquid compositions including valsartan | |
| TWI649097B (en) | Injectable preparation of acetaminophen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: HUNAN DINUO PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: WANG SHIQI Effective date: 20140805 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 410331 CHANGSHA, HUNAN PROVINCE TO: 410329 CHANGSHA, HUNAN PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20140805 Address after: 410329 Liuyang biological pharmaceutical industry park, Changsha, Hunan Province Patentee after: HUNAN DINUO PHARMACEUTICAL Co.,Ltd. Address before: 410331 national biological industry base of Changsha, Hunan Patentee before: Wang Shiqi |
|
| CP03 | Change of name, title or address |
Address after: 410005 Kangping Road, Liuyang economic and Technological Development Zone, Changsha, Hunan, 165 Patentee after: HUNAN DINUO PHARMACEUTICAL Co.,Ltd. Address before: 410329 Huan Yuan East Road, Liuyang biological pharmaceutical industrial park, Changsha, Hunan Patentee before: HUNAN DINUO PHARMACEUTICAL Co.,Ltd. |
|
| CP03 | Change of name, title or address | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Pharmaceutical composition containing diclofenac sodium and paracetamol Effective date of registration: 20221213 Granted publication date: 20130213 Pledgee: China Construction Bank Corporation Liuyang sub branch Pledgor: HUNAN DINUO PHARMACEUTICAL Co.,Ltd. Registration number: Y2022980026992 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right |